In vivo radioimaging of bradykinin receptor B1, a widely overexpressed molecule in human cancer

Cancer Research

Volumn 75, Issue 2, 2015, Pages 387-393

  Lin, Kuo Shyan ^a,b   Pan, Jinhe ^a   Amouroux, Guillaume ^a   Turashvili, Gulisa ^a   Mesak, Felix ^a   Hundal Jabal, Navjit ^a   Pourghiasian, Maral ^a   Lau, Joseph ^a   Jenni, Silvia ^a   Aparicio, Samuel ^a,b   Benard, Francois ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B1 RECEPTOR; ENALAPRILAT; GALLIUM TETRAXETAN AMINOHEXANOIC ACID [4 HYDROXYPROLINE 6 CHA 9 LEUCINE 10 DESARGININE]KALLIDIN GA 68; GALLIUM TETRAXETAN AMINOHEXANOIC ACID [9 LEUCIN 10 DESARGININE]KALLIDIN GA 68; GALLIUM TETRAXETAN POLYETHYLENE GLYCOL 2 [4 HYDROXYPROLINE 6 CHA 9 LEUCINE 10 DESARGININE]KALLIDIN GA 68; KALLIDIN DERIVATIVE; PEPTIDASE; PHOSPHORAMIDON; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GALLIUM; ORGANOMETALLIC COMPOUND; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; EMBRYO; ENZYME INHIBITION; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MOUSE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIOCHEMISTRY; RADIOGRAPHY; RECEPTOR BINDING; RECEPTOR BLOCKING; SEQUENCE ANALYSIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; DIAGNOSTIC USE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCINTISCANNING;

ANIMALS; GALLIUM RADIOISOTOPES; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, BRADYKININ B1;

EID: 84920997436     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1603     Document Type: Article

References (20)

1. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3:845-52.
2. da Costa PL, Sirois P, Tannock IF, ChammasR. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2014;345:27-38.
3. Molina L, Matus CE, Astroza A, Pavicic F, Tapia E, Toledo C, et al. Stimulation of the bradykinin B(1) receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat 2009;118:499-510.
4. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63:2037-41.
5. Ehrenfeld P, Conejeros I, Pavicic MF, Matus CE, Gonzalez CB, Quest AF, et al. Activation of kinin B1 receptor increases the release of metalloproteases-2 and-9 from both estrogen-sensitive and-insensitive breast cancer cells. Cancer Lett 2011;301:106-18.
6. Yu HS, Lin TH, Tang CH. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCdelta/c-Src dependent signaling pathway. Prostate 2013;73:89-100.
7. Kashuba E, Bailey J, Allsup D, Cawkwell L. The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers 2013;18:279-96.
8. Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 2002;8:1280-7.
9. Stewart JM, Chan DC, Simkeviciene V, Bunn PA Jr, Helfrich B, York EJ, et al. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol 2002;2:1781-6.
10. Bawolak MT, Gera L, Morissette G, Bouthillier J, Stewart JM, Gobeil LA, et al. Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression. J Pharmacol Exp Ther 2009;329:159-68.
11. Gera L, Roy C, Bawolak MT, Charest-Morin X, Marceau F. N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Peptides 2012;34:433-46.
12. Stahl W, Breipohl G, Kuhlmann L, Steinstrasser A, Gerhards HJ, Scholkens BA. Technetium-99m-labeledHOE140: a potential bradykinin B2 receptor imaging agent. J Med Chem 1995;38:2799-801.
13. Fuchs K, Fischer K, Schwenck J, Kesenheimer C, Abbas S, Stiller D, et al. In vivo PET imaging of Bradykinin Receptor 1 (B1R) expression in a mouse model of chronic inflammation. World Molecular Imaging Congress. San Diego, CA; 2011. p. T103.
14. Haddad EB, Fox AJ, Rousell J, Burgess G, McIntyre P, Barnes PJ, et al. Posttranscriptional regulation of bradykinin B1 and B2 receptor gene expression in human lung fibroblasts by tumor necrosis factor-alpha: modulation by dexamethasone. Mol Pharmacol 2000;57:1123-31.
15. Matsas R, Kenny AJ, Turner AJ. The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24. 11. Biochem J 1984;223:433-40.
16. Nock BA, Maina T, Krenning EP, de Jong M. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med 2014;55:121-7.
17. Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 2000;278:H1069-74.
18. Vegt E, Melis M, Eek A, de Visser M, BromM, Oyen WJ, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011;38:623-32.
19. Lin M, Welch MJ, Lapi SE. Effects of chelator modifications on (68)Galabeled [Tyr (3)]octreotide conjugates. Mol Imaging Biol 2013;15: 606-13.
20. Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med 2012;53:1481-9.